$10M Novartis drug faces threat

Posted 3 March 2025 AM 

Novartis’ fast-growing kinase inhibitor Rydapt has been hit with the first copycat on the ARTG.

The TGA has approved Dr Reddy’s generic brands Midostaurin Dr.Reddy’s and Midostaurin-RZ for the same indications as Rydapt, which is used for the treatment of adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasms (SM-AHN) or mast cell leukaemia (MCL).

To see the whole article, please login